UniQure

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

uniQure will seek an early 2026 follow-up meeting after staff signaled Phase I/II results are unlikely to provide primary evidence for a BLA.